Cargando…

The Limitless Future of RNA Therapeutics

Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize per...

Descripción completa

Detalles Bibliográficos
Autores principales: Damase, Tulsi Ram, Sukhovershin, Roman, Boada, Christian, Taraballi, Francesca, Pettigrew, Roderic I., Cooke, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012680/
https://www.ncbi.nlm.nih.gov/pubmed/33816449
http://dx.doi.org/10.3389/fbioe.2021.628137
_version_ 1783673415914225664
author Damase, Tulsi Ram
Sukhovershin, Roman
Boada, Christian
Taraballi, Francesca
Pettigrew, Roderic I.
Cooke, John P.
author_facet Damase, Tulsi Ram
Sukhovershin, Roman
Boada, Christian
Taraballi, Francesca
Pettigrew, Roderic I.
Cooke, John P.
author_sort Damase, Tulsi Ram
collection PubMed
description Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA constructs. In this review we discuss general concepts of different classes of RNA-based therapeutics, including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA. Furthermore, we provide an overview of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. The challenges and advantages associated with use of RNA-based drugs are also discussed along with various approaches for RNA delivery. In addition, we introduce a new concept of hospital-based RNA therapeutics and share our experience with establishing such a platform at Houston Methodist Hospital.
format Online
Article
Text
id pubmed-8012680
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80126802021-04-02 The Limitless Future of RNA Therapeutics Damase, Tulsi Ram Sukhovershin, Roman Boada, Christian Taraballi, Francesca Pettigrew, Roderic I. Cooke, John P. Front Bioeng Biotechnol Bioengineering and Biotechnology Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA constructs. In this review we discuss general concepts of different classes of RNA-based therapeutics, including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA. Furthermore, we provide an overview of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. The challenges and advantages associated with use of RNA-based drugs are also discussed along with various approaches for RNA delivery. In addition, we introduce a new concept of hospital-based RNA therapeutics and share our experience with establishing such a platform at Houston Methodist Hospital. Frontiers Media S.A. 2021-03-18 /pmc/articles/PMC8012680/ /pubmed/33816449 http://dx.doi.org/10.3389/fbioe.2021.628137 Text en Copyright © 2021 Damase, Sukhovershin, Boada, Taraballi, Pettigrew and Cooke. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Damase, Tulsi Ram
Sukhovershin, Roman
Boada, Christian
Taraballi, Francesca
Pettigrew, Roderic I.
Cooke, John P.
The Limitless Future of RNA Therapeutics
title The Limitless Future of RNA Therapeutics
title_full The Limitless Future of RNA Therapeutics
title_fullStr The Limitless Future of RNA Therapeutics
title_full_unstemmed The Limitless Future of RNA Therapeutics
title_short The Limitless Future of RNA Therapeutics
title_sort limitless future of rna therapeutics
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012680/
https://www.ncbi.nlm.nih.gov/pubmed/33816449
http://dx.doi.org/10.3389/fbioe.2021.628137
work_keys_str_mv AT damasetulsiram thelimitlessfutureofrnatherapeutics
AT sukhovershinroman thelimitlessfutureofrnatherapeutics
AT boadachristian thelimitlessfutureofrnatherapeutics
AT taraballifrancesca thelimitlessfutureofrnatherapeutics
AT pettigrewroderici thelimitlessfutureofrnatherapeutics
AT cookejohnp thelimitlessfutureofrnatherapeutics
AT damasetulsiram limitlessfutureofrnatherapeutics
AT sukhovershinroman limitlessfutureofrnatherapeutics
AT boadachristian limitlessfutureofrnatherapeutics
AT taraballifrancesca limitlessfutureofrnatherapeutics
AT pettigrewroderici limitlessfutureofrnatherapeutics
AT cookejohnp limitlessfutureofrnatherapeutics